uniQure (NASDAQ:QURE) Price Target Raised to $20.00

uniQure (NASDAQ:QURE) had its price target raised by equities researchers at Royal Bank of Canada from $14.00 to $20.00 in a report released on Wednesday,Benzinga reports. The firm presently has an “outperform” rating on the biotechnology company’s stock. Royal Bank of Canada’s price objective would suggest a potential upside of 32.63% from the stock’s previous close.

Several other equities research analysts have also commented on QURE. The Goldman Sachs Group dropped their price objective on shares of uniQure from $10.00 to $9.00 and set a “neutral” rating on the stock in a research note on Wednesday, November 6th. HC Wainwright reiterated a “buy” rating and set a $25.00 price target on shares of uniQure in a report on Tuesday. StockNews.com raised uniQure to a “sell” rating in a research report on Wednesday. Cantor Fitzgerald raised their target price on shares of uniQure from $28.00 to $58.00 and gave the stock an “overweight” rating in a report on Tuesday. Finally, Raymond James raised uniQure from an “outperform” rating to a “strong-buy” rating and lifted their price objective for the stock from $20.00 to $52.00 in a report on Tuesday. One research analyst has rated the stock with a sell rating, two have assigned a hold rating, three have given a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $28.33.

uniQure Trading Down 1.4 %

Shares of QURE stock traded down $0.22 during trading hours on Wednesday, reaching $15.08. The company’s stock had a trading volume of 2,345,300 shares, compared to its average volume of 1,621,595. The stock has a market capitalization of $735.00 million, a P/E ratio of -3.04 and a beta of 0.89. The firm’s fifty day simple moving average is $6.42 and its 200 day simple moving average is $6.15. uniQure has a one year low of $3.73 and a one year high of $17.39. The company has a current ratio of 6.51, a quick ratio of 6.51 and a debt-to-equity ratio of 0.92.

uniQure (NASDAQ:QURE) last announced its earnings results on Tuesday, November 5th. The biotechnology company reported ($0.91) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.12) by $0.21. uniQure had a negative return on equity of 188.82% and a negative net margin of 837.80%. The firm had revenue of $2.29 million during the quarter, compared to analyst estimates of $2.73 million. Equities research analysts expect that uniQure will post -3.74 EPS for the current year.

Insider Transactions at uniQure

In related news, CEO Matthew C. Kapusta sold 3,418 shares of uniQure stock in a transaction that occurred on Monday, December 9th. The stock was sold at an average price of $7.63, for a total transaction of $26,079.34. Following the sale, the chief executive officer now owns 597,915 shares of the company’s stock, valued at approximately $4,562,091.45. This trade represents a 0.57 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Corporate insiders own 4.74% of the company’s stock.

Institutional Investors Weigh In On uniQure

A number of institutional investors have recently added to or reduced their stakes in the stock. RTW Investments LP purchased a new position in uniQure during the third quarter valued at $49,000. China Universal Asset Management Co. Ltd. lifted its stake in uniQure by 57.0% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 10,093 shares of the biotechnology company’s stock worth $50,000 after purchasing an additional 3,663 shares in the last quarter. Atria Investments Inc bought a new position in shares of uniQure during the 3rd quarter valued at about $53,000. Quarry LP purchased a new position in shares of uniQure during the third quarter valued at about $58,000. Finally, Vanguard Personalized Indexing Management LLC increased its holdings in shares of uniQure by 21.0% in the second quarter. Vanguard Personalized Indexing Management LLC now owns 13,301 shares of the biotechnology company’s stock worth $59,000 after purchasing an additional 2,306 shares during the last quarter. 78.83% of the stock is owned by hedge funds and other institutional investors.

About uniQure

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.